Omamah Alfarisi

Research Associate

If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Rifampin Medicine & Life Sciences
rifapentine Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Tuberculosis Medicine & Life Sciences
Tenofovir Medicine & Life Sciences
Pyrazinamide Medicine & Life Sciences
Latent Tuberculosis Medicine & Life Sciences
Diabetes Mellitus Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2017 2019

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

Cerrone, M., Alfarisi, O., Neary, M., Marzinke, M. A., Parsons, T. L., Owen, A., Maartens, G., Pozniak, A., Flexner, C. W. & Boffito, M., Jun 1 2019, In : The Journal of antimicrobial chemotherapy. 74, 6, p. 1670-1678 9 p.

Research output: Contribution to journalArticle


Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment

Alfarisi, O., Mave, V., Gaikwad, S., Sahasrabudhe, T., Ramachandran, G., Kumar, H., Gupte, N., Kulkarni, V., Deshmukh, S., Atre, S., Raskar, S., Lokhande, R., Barthwal, M., Kakrani, A., Chon, S., Gupta, A., Golub, J. E. & Dooley, K. E., Nov 1 2018, In : Antimicrobial Agents and Chemotherapy. 62, 11

Research output: Contribution to journalArticle

Diabetes Mellitus

Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

Alfarisi, O., Alghamdi, W. A., Al-Shaer, M. H., Dooley, K. E. & Peloquin, C. A., Aug 19 2017, (Accepted/In press) In : Expert Review of Clinical Pharmacology. p. 1-10 10 p.

Research output: Contribution to journalArticle

Latent Tuberculosis
Drug Interactions